AXT (AXTI) Q1 2026 Earnings Call Transcript

AXT reported Q1 revenue of $26.9 million, up from $23.0 million, with non-GAAP gross margin improving to 29.9% from 21.5% and Q2 guidance calling for profitability. Management said indium phosphide revenue will set a new quarterly record above $17 million in Q2, backed by a record $100 million+ backlog and a $632.5 million capital raise to expand capacity. The main risk remains export permit timing, but demand tied to AI/data center infrastructure and China growth is accelerating.

Analysis

AXTI is transitioning from a cyclical substrate supplier to a capacity-constrained, permit-gated AI infrastructure beneficiary. The key second-order effect is that backlog and pricing power are becoming more durable because the bottleneck is no longer demand, but export authorization and wafer format migration; that shifts leverage toward whichever customers can secure permits and commit to longer-dated take-or-pay style supply. The capital raise changes the equity story from survival to expansion, but it also raises the bar: execution will now be judged on whether incremental capex converts into actual shipped revenue, not just headline capacity.

The market is likely underappreciating how strong mix shift can be even before full utilization peaks. The move toward larger-diameter, higher-spec product should keep gross margin expanding faster than revenue, and the raw-material vertical integration creates an internal hedge against input inflation that most peers lack. The downside is that receivables and inventory are already rising alongside cash burn, which can mask true working-capital intensity if permits slip; if shipments are delayed, the company could look operationally healthy while quietly absorbing more balance-sheet strain.

The most important catalyst window is the next 1-2 quarters, where realized permit approvals will determine whether the company can hit the implied step-up in revenue and turn the profit inflection from guidance into a print. A contrarian concern is that consensus may be extrapolating a capacity roadmap that is faster than the permitting regime can monetize, especially for U.S.-linked demand. If permit timing disappoints, the stock can re-rate quickly because the market is effectively paying for visible conversion of backlog into cash flow, not just optimistic TAM math.

Key Decisions for Investors

• Long AXTI into the next 1-2 earnings prints if the stock has not already re-rated aggressively; thesis is permit-driven revenue conversion plus gross margin expansion, with upside if Q2/Q3 shipments track guidance and downside bounded by strong liquidity.
• Use a call spread in AXTI rather than outright equity for the next 60-90 days; the risk/reward is skewed to a discrete re-rating on permit approvals, while capping premium if timing slips.
• Pair trade: long AXTI / short a less vertically integrated semiconductor materials peer that lacks captive raw material supply and has slower capacity response; the spread should widen if pricing and mix improvement persist.
• Fade any parabolic move above the implied execution line by trimming 25-50% of exposure if the market starts discounting 2027-2028 capacity before permits are proven; the key risk is narrative outrunning realized shipments.
• Monitor working capital weekly; if receivables and inventory continue to rise faster than revenue, reduce exposure because the next leg of the story becomes balance-sheet absorption rather than operating leverage.